Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D). Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.
121 Seaport Blvd
Boston, MA 02210
Brief summary of the
materials and/or video content:
Understanding the Mechanism of Disease and Effect of LOW ALP in the human body
Have questions? Please contact:
Madoc Walmsley - 501-247-4961